This article was originally published in The Tan Sheet
Hawthorne, N.Y.-based firm cites advertising expenses in support of ElixSure cough/cold and Kerasal moisturizer lines as a reason for an approximate 55% reduction in first-quarter net earnings to $5 mil. Overall sales declined approximately 7% to $84.1 mil., Taro reported April 26. The costs were incurred prior to the product lines' March divestment, the company maintains. Taro turned over North American marketing and distribution rights for the lines to Alterna in March (1"The Tan Sheet" March 7, 2005, p. 11)...
You may also be interested in...
Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market
As the US heads into a COVID-19 storm with grave concerns about the lack of face masks and respirators for health care workers, the FDA has further relaxed federal oversight for such products, giving more responsibility to employers
FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.